Scientific Sessions 2025  /  Targeting Inflammation in Coronary Atherosclerosis  /  Does Lipoprotein(a) Associate with In-Stent Neoatherosclerosis and Plaque Vulnerability Detected by Optical Coherence Tomography in Patients with Acute Coronary Syndrome?
Logo

American Heart Association

  54
  0

Final ID: 4363863

Does Lipoprotein(a) Associate with In-Stent Neoatherosclerosis and Plaque Vulnerability Detected by Optical Coherence Tomography in Patients with Acute Coronary Syndrome?

Abstract Body (Do not enter title and authors here): Background: Recently, lipoprotein(a) [Lp(a)], a genetically determined low-density lipoprotein-like particle, has been recognized as a potential therapeutic target for residual cardiovascular risk. In-stent restenosis remains one of major clinical challenges for patients undergoing stent implantation. This study aimed to investigate the association between Lp(a) level and optical coherence tomography (OCT)-defined ISNA as well as plaque vulnerability in patients with acute coronary syndrome (ACS).
Methods: From January 2017 to December 2021, 146 ACS patients with ISR undergoing OCT-guided intervention were enrolled. Baseline serum Lp(a) levels were measured via latex particle-enhanced turbidimetric immunoassay (Roche Diagnostics) and categorized into high (≥75 nmol/L, n=34) and low (<75 nmol/L, n=112) groups. Clinical profiles, angiographic features, and OCT data were compared between groups. Multivariate logistic regression adjusted for covariates was performed to identify independent associations. The primary endpoint was the presence of in-stent neoatherosclerosis (ISNA).
Results: The cohort had a mean age of 62.3±8.9 years, with 73.3% (107/146) males. Elevated Lp(a) (≥75 nmol/L) was observed in 23.3% (34/146) of patients. Compared to the low Lp(a) group, the high Lp(a) group exhibited significantly higher rates of ISNA (91.2% vs. 50.9%, P<0.001), thin-cap fibroatheroma (TCFA) (38.2% vs. 8.0%, P<0.001), macrophage accumulation (82.4% vs. 64.3%, P=0.047). Conversely, homogeneous neointima was more prevalent in the low Lp(a) group (41.1% vs. 4.2%, P<0.001). Multivariate analysis confirmed that elevated Lp(a) independently correlated with ISNA (OR: 1.012, 95% CI: 1.004–1.020; P=0.002) and TCFA (OR: 1.010, 95% CI: 1.005–1.016; P<0.001).
Conclusion: In ACS patients with ISR, Lp(a) ≥75 nmol/L is independently associated with increased risks of ISNA and vulnerable plaque phenotypes. These findings highlight the potential role of Lp(a) in ISR pathogenesis and suggest its utility in risk stratification and targeted therapeutic strategies.
  • Chen, Jiawen  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Xu, Yishuo  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Li, Lulu  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Wang, Yini  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Xu, Xing  ( Beijing Novartis Pharma Co., Ltd. , Beijing , China )
  • Chen, Ting  ( Beijing Novartis Pharma Co., Ltd. , Beijing , China )
  • Dai, Jiannan  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Fang, Chao  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Yu, Bo  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Gao, Shengen  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Dong, Fuhong  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Huang, Dongxu  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Cui, Lina  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Ma, Xianqin  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Zhao, Jiawei  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Chen, Yuzhu  ( Harbin Medical University, 2nd hosp , Harbin , China )
  • Zhao, Rui  ( Harbin Medical University, 2nd hosp , Harbin , China )
    • Author Disclosures:
    Jiawen Chen: DO NOT have relevant financial relationships | yishuo xu: No Answer | lulu li: No Answer | yini wang: No Answer | Xing Xu: DO NOT have relevant financial relationships | ting chen: No Answer | Jiannan Dai: No Answer | Chao Fang: No Answer | Bo Yu: DO have relevant financial relationships ; Research Funding (PI or named investigator):Beijing Novartis Pharmaceutical Company:Active (exists now) | Shengen Gao: DO NOT have relevant financial relationships | fuhong dong: No Answer | Dongxu Huang: No Answer | Lina Cui: DO NOT have relevant financial relationships | xianqin ma: No Answer | jiawei zhao: No Answer | Yuzhu Chen: No Answer | rui zhao: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Targeting Inflammation in Coronary Atherosclerosis

Monday, 11/10/2025 , 09:45AM - 11:00AM

Abstract Oral Session

More abstracts on this topic:
Association of Elevated Lipoprotein(a) Levels with Adverse Outcomes in Patients with Stable Angina Undergoing Stent-less PCI with Paclitaxel-coated Balloon

Takahashi Tomonori, Yamaguchi Koji, Yagi Shusuke, Yamada Hirotsugu, Soeki Takeshi, Sata Masataka, Wakatsuki Tetsuzo, Saijo Yoshihiro, Kawabata Yutaka, Ueno Rie, Kadota Muneyuki, Hara Tomoya, Matsuura Tomomi, Ise Takayuki

A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation

Mouawad Sahar, Boffa Michael, Koschinsky Marlys

More abstracts from these authors:
Efficacy and Safety of Extended Dual Antiplatelet Therapy in Stable Patients With Multivessel Coronary Artery Disease Undergoing Drug-Eluting Stent Implantation (DAPT-MVD): An Investigator-Initiated, Multicenter, Randomized, Open-Label, Assessor-Masked, Superiority Trial

Tian Jinwei, Yu Xi, Gao Guangren, Liu Ying, Zhao Jie, Hou Xinyu, Qin Zhexue, Lu Haijing, Zhang Shujiang, Li Shengli, Weng Zhiyuan, Wang Zhuozhong, Tang Huifang, He Yuquan, Zhang Chunpeng, Liu Yong, Jiang Jun, Zhang Jinying, Cai Lei, Mintz Gary, Wang Duolao, Stone Gregg, Wang Yan, Yu Bo, Xiao Jiandong, Wang Fan, Peng Xiang, Li Chunjie, Zhao Peng, Tong Qian

4363863_File000000.jpg
4363863_File000000.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available